Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Alexander M. Lesokhin, MD, Moshe Y. Levy, MD, Andrew P. Dalovisio, MD, Nizar J. Bahlis, MD, Melhem Solh, MD, Michael Sebag, MD PhD FRCPC, Andrzej Jakubowiak, MD PhD, Yogesh S. Jethava, MBBS, MD FRCPath, MRCP, Caitlin L. Costello, MD, Michael P. Chu, MD, Michael R. Savona, MD, Cristina Gasparetto, MD, Suzanne Trudel, MD MSC, FRCPC, Jeffrey Chou, MD PhD, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Heike I. Krupka, PhD PMP, Noopur S. Raje, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133355

Published: 2020

Journal Articles

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Rin Nakamura, Sean Lear, Deanna Wilson, Hartmut Koeppen, Anjali Vaze, Suzanne Trudel, MD MSC, FRCPC, Andrew Spencer, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Adam D. Cohen, MD, Bernard M Fine, Mengsong Li, James Cooper, Teiko Sumiyoshi

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136980

Published: 2020

Journal Articles

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Blood (2014) 124 (21): 4773.

https://doi.org/10.1182/blood.V124.21.4773.4773

Published: 2014

Journal Articles

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Victor H Jimenez Zepeda, MD, Suzanne Trudel, MD, MSC, FRCPC, Donna E. Reece, MD, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Norman Franke, MD, Andrew Winter, Sr., RN, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3396.

https://doi.org/10.1182/blood.V122.21.3396.3396

Published: 2013

Journal Articles

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

Danielle C Croucher, MSc, BSc, Zhihua Li, Brent D.G. Page, PhD, Ellen Nong Wei, Patrick T. Gunning, PhD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2013) 122 (21): 4441.

https://doi.org/10.1182/blood.V122.21.4441.4441

Published: 2013

Journal Articles

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

Blood (2013) 122 (21): 1942.

https://doi.org/10.1182/blood.V122.21.1942.1942

Published: 2013

Journal Articles

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Blood (2013) 122 (21): 1988.

https://doi.org/10.1182/blood.V122.21.1988.1988

Published: 2013

Journal Articles

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Sophia Farooki, MD, FRCPC, Manjula Maganti, Donna E Reece, MD, FRCPC, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5315.

https://doi.org/10.1182/blood.V122.21.5315.5315

Published: 2013

Journal Articles

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Erik H van Beers, PhD, Martin H. Van Vliet, PhD, Kenneth C. Anderson, MD, Ajai Chari, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Shaji K Kumar, MD, Daniel Lebovic, MD, Joan Levy, PhD, Sagar Lonial, M.D., Donna E Reece, MD, FRCPC, Paul G. Richardson, MD, David S Siegel, MD, PhD, Keith Stewart, MBA, MB, CHB, Suzanne Trudel, MD, MSC, FRCPC, Ravi Vij, MD, Todd M. Zimmerman, MD, Rafael Fonseca, M.D.

Blood (2013) 122 (21): 1854.

https://doi.org/10.1182/blood.V122.21.1854.1854

Published: 2013

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Victor H Jimenez Zepeda, MD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP, FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5398.

https://doi.org/10.1182/blood.V122.21.5398.5398

Published: 2013

Journal Articles

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Christine I. Chen, MD, Susi Snitzler, RN, Trina Wang, RN, Harminder Paul, Lisa W Le, Ellen Nong Wei, MSc, Anthea Lau, Deborah A Smith, PharmD, Michelle Brown, James B Johnston, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2013) 122 (21): 4175.

https://doi.org/10.1182/blood.V122.21.4175.4175

Published: 2013

Journal Articles

Absolute Lymphocyte Count At Day+15 and +30 Post-ASCT As Predictors of Early and 1-Year Mortality for Patients with AL Amyloidosis Treated with a Single Autologous Stem Cell Transplant

Victor Hugo Jimenez-Zepeda, MD PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4518.

https://doi.org/10.1182/blood.V120.21.4518.4518

Published: 2012

Journal Articles

Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience

Rouslan Kotchetkov, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Young Trieu, Saima Dean, Manjula Maganti, Christine I. Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, MSC, FRCPC, Donna E. Reece, MD, FRCPC

Blood (2012) 120 (21): 1867.

https://doi.org/10.1182/blood.V120.21.1867.1867

Published: 2012

Journal Articles

Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy

Mark D. Minden, MD, PhD, FRCPC, Donna E. Hogge, MD, PhD, FRCPC, Scott Weir, PharmD, PhD, Jim Kasper, MS, Lavonne Patton, PhD, Yulia Jitkova, PhD, Marcela Gronda, MSc, Rose Hurren, BSc, Lian Rajewski, Kevin Schorno, MBA, Hong Chang, Joseph M. Brandwein, MD, Vikas Gupta, MD, FRCP, FRCPath, Andre C. Schuh, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Karen W.L. Yee, MD, FRCP, Greg Reed, Aaron D Schimmer, MD, PhD

Blood (2012) 120 (21): 1372.

https://doi.org/10.1182/blood.V120.21.1372.1372

Published: 2012

Journal Articles

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Victor H Jimenez-Zepeda, MD, PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD, FRACP, FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4064.

https://doi.org/10.1182/blood.V120.21.4064.4064

Published: 2012

Journal Articles

BP-2-047, a Novel Small-Molecule Inhibitor of Stat3 Is Active in Myeloma Pre-Clinical Models: Rationale for Treatment of Stat3-Dependent Multiple Myeloma

Victor Hugo Jimenez-Zepeda, MD, Brent DG Page, BS, Li Zhia Hua, Ellen Wei, Leif Bergsagel, M.D., Patrick T Gunning, PhD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2012) 120 (21): 576.

https://doi.org/10.1182/blood.V120.21.576.576

Published: 2012

Journal Articles

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

Victor Hugo Jimenez-Zepeda, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD FRACP FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 595.

https://doi.org/10.1182/blood.V120.21.595.595

Published: 2012

Journal Articles

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Danielle C Croucher, Victor H Jimenez-Zepeda, MD, PD, Zhi Hua Li, Ellen Wei, Brent DG Page, James Turkson, Patrick T Gunning, Suzanne Trudel, MD, MSC, FRCPC

Blood (2011) 118 (21): 5101.

https://doi.org/10.1182/blood.V118.21.5101.5101

Published: 2011

Journal Articles

CYBOR-D Induction Therapy In Clinical Practice

Christine Chen, MD, Esther Masih-Khan, PhD, Victor Jimenez-Zepeda, MD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 5136.

https://doi.org/10.1182/blood.V118.21.5136.5136

Published: 2011

Journal Articles

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Christine Chen, MD, MEd, FRCPC, Ahmed M. Rabea, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Vishal Kukreti, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 3983.

https://doi.org/10.1182/blood.V118.21.3983.3983

Published: 2011

NARROW

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Absolute Lymphocyte Count At Day+15 and +30 Post-ASCT As Predictors of Early and 1-Year Mortality for Patients with AL Amyloidosis Treated with a Single Autologous Stem Cell Transplant

Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience

Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

BP-2-047, a Novel Small-Molecule Inhibitor of Stat3 Is Active in Myeloma Pre-Clinical Models: Rationale for Treatment of Stat3-Dependent Multiple Myeloma

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

CYBOR-D Induction Therapy In Clinical Practice

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only